AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration

Stock News03-05

AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase follows an announcement of a collaboration agreement between AKESO and INOVIO. The partnership will involve cooperation with Dana Farber Cancer Institute, a world-leading cancer research organization, and Mass General Brigham, a top-tier healthcare group, to jointly explore innovative treatments for glioblastoma (GBM). The research will focus on combining AKESO's globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, with INOVIO's DNA-based therapeutic INO-5412. Dr. Xia Yu, Founder, Chairman, President, and CEO of AKESO, stated that cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy. She emphasized that AKESO is accelerating the global development of cadonilimab through a diversified strategy of in-house development and international collaboration. The company aims to fully explore the groundbreaking clinical value and international potential of cadonilimab as a cornerstone agent for combination immunotherapy, thereby advancing cancer immunotherapy into its next phase of development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131078244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131078244","market":"fut","top_or_hot":-1,"title":"AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration","media":"Stock News","content":"<p>AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase follows an announcement of a collaboration agreement between AKESO and INOVIO. The partnership will involve cooperation with Dana Farber Cancer Institute, a world-leading cancer research organization, and Mass General Brigham, a top-tier healthcare group, to jointly explore innovative treatments for glioblastoma (GBM). The research will focus on combining AKESO's globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, with INOVIO's DNA-based therapeutic INO-5412. Dr. Xia Yu, Founder, Chairman, President, and CEO of AKESO, stated that cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy. She emphasized that AKESO is accelerating the global development of cadonilimab through a diversified strategy of in-house development and international collaboration. The company aims to fully explore the groundbreaking clinical value and international potential of cadonilimab as a cornerstone agent for combination immunotherapy, thereby advancing cancer immunotherapy into its next phase of development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-05 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase follows an announcement of a collaboration agreement between AKESO and INOVIO. The partnership will involve cooperation with Dana Farber Cancer Institute, a world-leading cancer research organization, and Mass General Brigham, a top-tier healthcare group, to jointly explore innovative treatments for glioblastoma (GBM). The research will focus on combining AKESO's globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, with INOVIO's DNA-based therapeutic INO-5412. Dr. Xia Yu, Founder, Chairman, President, and CEO of AKESO, stated that cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy. She emphasized that AKESO is accelerating the global development of cadonilimab through a diversified strategy of in-house development and international collaboration. The company aims to fully explore the groundbreaking clinical value and international potential of cadonilimab as a cornerstone agent for combination immunotherapy, thereby advancing cancer immunotherapy into its next phase of development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0540923850.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1131078244","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131078244","pubTimestamp":1772678314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","BK4585":"ETF&股票定投概念","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","VT":"世界全股市ETF-Vanguard","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","09926":"康方生物","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK4139":"生物科技","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK4109":"特种化学制品","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK4588":"碎股","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","BK1161":"生物科技","DNA":"Ginkgo Bioworks Holdings Inc.","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK4121":"生命科学工具和服务","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"康方生物股价早盘因新型脑癌治疗合作飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"DNA":1,"VT":1,"VXUS":1},"content_text":"AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase follows an announcement of a collaboration agreement between AKESO and INOVIO. The partnership will involve cooperation with Dana Farber Cancer Institute, a world-leading cancer research organization, and Mass General Brigham, a top-tier healthcare group, to jointly explore innovative treatments for glioblastoma (GBM). The research will focus on combining AKESO's globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, with INOVIO's DNA-based therapeutic INO-5412. Dr. Xia Yu, Founder, Chairman, President, and CEO of AKESO, stated that cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy. She emphasized that AKESO is accelerating the global development of cadonilimab through a diversified strategy of in-house development and international collaboration. The company aims to fully explore the groundbreaking clinical value and international potential of cadonilimab as a cornerstone agent for combination immunotherapy, thereby advancing cancer immunotherapy into its next phase of development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131078244","isCrawlerRequest":true}